# Phase 2 arthritis trials recruiting: 54 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 54 trials in phase 2 for arthritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 arthritis trials: 54 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/arthritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 54
- Recruiting or not yet: 54
- Read on: November 19, 2026

## Trials

The 25 newest of 54, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07923773 | Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension) | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Moderate to Severe Psoriatic Arthritis | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923773) |
| October 29, 2026 | NCT07904754 | Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis | AbbVie | Phase 2 | Not yet recruiting | Rheumatoid Arthritis | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904754) |
| October 26, 2026 | NCT07895524 | A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) | Merck Sharp & Dohme LLC | Phase 2 | Not yet recruiting | Rheumatoid Arthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895524) |
| October 9, 2026 | NCT07869134 | Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis | Forward Therapeutics | Phase 2 | Not yet recruiting | Psoriatic Arthritis (PsA) | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869134) |
| October 8, 2026 | NCT07864688 | Evaluation of Dapagliflozin and Empagliflozin as Adjunctive Therapy to Methotrexate in Patients With Rheumatoid Arthritis | Al-Azhar University | Phase 2 | Not yet recruiting | Rheumatoid Arthritis (RA) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864688) |
| September 3, 2026 | NCT07801495 | A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis | Novartis Pharmaceuticals | Phase 2 | Recruiting | Moderate to Severe Psoriatic Arthritis | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801495) |
| September 1, 2026 | NCT07796516 | Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis | Peking University People's Hospital | Phase 2 | Recruiting | Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796516) |
| August 21, 2026 | NCT07779616 | Study of PTC844 in Participants With Active Rheumatoid Arthritis | PTC Therapeutics | Phase 2 | Recruiting | Rheumatoid Arthritis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779616) |
| August 6, 2026 | NCT07748624 | A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE)... | Novartis Pharmaceuticals | Phase 2 | Recruiting | VEXAS Syndrome | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748624) |
| August 4, 2026 | NCT07745426 | Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis | Tanta University | Phase 2 | Recruiting | Rheumatoid Arthritis (RA) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745426) |
| July 16, 2026 | NCT07708181 | A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Gout Arthritis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708181) |
| July 15, 2026 | NCT07706530 | Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) | Clarent Biopharma, Inc. | Phase 2 | Not yet recruiting | Arthritic Psoriasis | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706530) |
| July 6, 2026 | NCT07684157 | A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis | Jacobio Pharmaceuticals Co., Ltd. | Phase 2 | Recruiting | Rheumatoid Arthritis (RA) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684157) |
| June 10, 2026 | NCT07639177 | Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis | Peking Union Medical College Hospital | Phase 2 | Recruiting | Rheumatoid Arthritis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639177) |
| June 8, 2026 | NCT07632872 | Desloratadine as Adjunct Therapy for Rheumatoid Arthritis | Horus University | Phase 2 | Recruiting | Rheumatoid Arthritis (RA), Rheumatoid Arthritis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632872) |
| June 8, 2026 | NCT07632846 | Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis | Horus University | Phase 2 | Recruiting | Rheumatoid Arthritis, Rheumatoid Arthritis (RA) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07632846) |
| June 3, 2026 | NCT07624994 | Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine | Centre Jean Perrin | Phase 2 | Not yet recruiting | Digital Osteoarthritis or Rheumatoid Arthritis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07624994) |
| June 2, 2026 | NCT07620392 | An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis | Hoffmann-La Roche | Phase 2 | Recruiting | Rheumatoid Arthritis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620392) |
| May 5, 2026 | NCT07566351 | Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis | Horus University | Phase 2 | Recruiting | Rheumatoid Arthritis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566351) |
| April 16, 2026 | NCT07534332 | Disulfiram in Rheumatoid Arthritis | University of Oklahoma | Phase 2 | Not yet recruiting | Rheumatoid Arthritis, Inflammation, Obesity | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07534332) |
| April 8, 2026 | NCT07517575 | Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis | R-Pharm International, LLC | Phase 2 | Recruiting | Juvenile Idiopathic Arthritis | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517575) |
| April 7, 2026 | NCT07515872 | Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis | ZetrOZ, Inc. | Phase 2 | Not yet recruiting | Arthritis, Osteo Arthritis of the Knee | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515872) |
| March 27, 2026 | NCT07497282 | Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis | Ain Shams University | Phase 2 | Not yet recruiting | Rheumatoid Arthritis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497282) |
| February 27, 2026 | NCT07440238 | Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Septic Arthritis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440238) |
| February 20, 2026 | NCT07423533 | Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who... | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Rheumatoid Arthritis | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423533) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 4 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 3 |
| Horus University | 3 |
| Tanta University | 2 |
| Peking University People's Hospital | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |
| Toll Biotech Co. Ltd. (Beijing) | 1 |
| [PTC Therapeutics](https://specstream.ai/data/clinical-trials/company/ptc-therapeutics) | 1 |
| [Changchun GeneScience Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/changchun-genescience-pharmaceutical-co-ltd) | 1 |
| Centre Jean Perrin | 1 |
| Artiva Biotherapeutics, Inc. | 1 |
| German University in Cairo | 1 |
| Odense University Hospital | 1 |
| University Medical Center Groningen | 1 |
| SynAct Pharma Aps | 1 |
| AHS Cancer Control Alberta | 1 |
| University of Oklahoma | 1 |
| [InventisBio Co., Ltd](https://specstream.ai/data/clinical-trials/company/inventisbio-co-ltd) | 1 |
| R-Pharm International, LLC | 1 |
| Jacobio Pharmaceuticals Co., Ltd. | 1 |
| VA Office of Research and Development | 1 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| Canada | 8 |
| China | 8 |
| Spain | 8 |
| France | 8 |
| Germany | 7 |
| Poland | 7 |
| Egypt | 7 |
| Italy | 6 |
| Argentina | 4 |
| Brazil | 4 |
| Hungary | 4 |
| Mexico | 4 |
| United Kingdom | 4 |
| Bulgaria | 3 |
| Portugal | 3 |
| Denmark | 3 |
| Japan | 2 |
| Puerto Rico | 2 |
| South Africa | 2 |
| Belgium | 2 |
| Czechia | 2 |
| Serbia | 2 |
| Netherlands | 2 |
| Russia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Women's health clinics in the United States](https://specstream.ai/data/businesses/womens-health-clinics/united-states)
- [Mortgage lenders in the United States](https://specstream.ai/data/businesses/mortgage-lenders/united-states)
- [Crane services in the United States](https://specstream.ai/data/businesses/crane-services/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Investment management firms in the United States](https://specstream.ai/data/businesses/investment-management-firms/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
